Manipulating DNA using CRISPR-Cas to lessen autismic symptoms in juvenile patients.

Started July 21, 2022

Abstract or project description

Manipulating DNA using CRISPR-Cas is often thought of as a futuristic idea. While it is true that some aspects of the technology are idealistic and problem inducing, many applications of CRISPR have been proven plausible in a number of cases in clinical settings. Treatments for monogenic autism could be next. Autism Spectrum Disorder (ASD) is related to other conditions; such as Fragile X Disorder and Rett Syndrome. Studies to examine the link between these medical conditions and combat their affects are well underway. \nThe challenges that face the scientific community when working with new, groundbreaking technology is unparalleled. However, there is much motivation to conquer these complications. \nThis review paper will ultimately focus on the state of the field as it is at present, along with realistic goals the biologists have set for the future. The paper will uncover the bioethics that surround altering the human genome without individual choice. The controversies at the center of CRISPR-Cas technology is paired with the discussion of the main difference between, what society deems "neurotypical" versus what is known to be "neurodiverse." Scientists at universities such as Harvard, MIT, and the University of Toronto are evolving the state of CRISPR-Cas delivery. Options such as AVV delivery are widely used and topics like in vivo and ex vivo methods are heavily researched in different medical settings. This paper will take a critical look at the current research and the new strategies regarding CRISPR delivery, prime editing, consequences of utilization, such as Off Target Effects (OTEs).